In the NILE study, a prospective, head-to-head study of 282 patients, leading with Guardant360 LDT detected 20% more patients with biomarkers than leading with tissue testing.24
Lead with liquid Lead with Guardant360® CDx
THE ANSWERS ARE IN OUR BLOOD


